PGEN Precigen, Inc.

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.

$2.45  -0.27 (-9.78%)
As of 01/27/2022 15:59:36 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1997
Outstanding shares:  206,738,499
Average volume:  1,581,934
Market cap:   $599,541,647
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKM5C84
Valuation   (See tab for details)
PE ratio:   -5.15
PB ratio:   4.27
PS ratio:   6.06
Return on equity:   -82.89%
Net income %:   -109.91%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy